Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Peter Georgantopoulos"'
Publikováno v:
Cancer Medicine, Vol 8, Iss 5, Pp 2233-2240 (2019)
Abstract Chronic lymphocytic leukemia (CLL) patients are at increased risk for major hemorrhage (MH). We examined incidence of and risk factors for MH in CLL patients before introduction of newer CLL therapies such as ibrutinib, which includes bleedi
Externí odkaz:
https://doaj.org/article/da2869cea09247beb4d185946867fc53
Autor:
Bo Cai, Peter Georgantopoulos, Gowtham A. Rao, Kathlyn Sue Haddock, Charles L. Bennett, Christopher T. Emrich, Jan M. Eberth, James R. Hébert
Publikováno v:
Annals of epidemiology. 59
Purpose To assess veteran-specific prostate cancer (PrCA) mortality-to-incidence ratios (MIR) in South Carolina's (SC) veteran population. Methods U.S. Veterans Health Administration electronic medical records from January 1999 to December 2015 ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd3d0299c56a0ce59a52c8d56fffcd5f
https://pubmed.ncbi.nlm.nih.gov/33836289
https://pubmed.ncbi.nlm.nih.gov/33836289
Autor:
Paul Ray, LeAnn B. Norris, Paul R. Yarnold, William J. M. Hrushesky, Charles L. Bennett, Joseph R. Berger, Robert C. Kane, Oliver Sartor, Rachel A. Sabol, Peter Georgantopoulos, Dennis W. Raisch, Laura Rose Bobolts, Akida Lebby, Zaina P. Qureshi, Virginia Noxon
Publikováno v:
Cancer Medicine
A 43‐year‐old female with multiple sclerosis developed urethral melanoma. The only potential risk factor was treatment with natalizumab, a humanized monoclonal antibody against α4 integrins. To investigate the risk‐exposure relationship, we re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d5a576b11cfe0f7c00a1ccf92d2db5
https://doi.org/10.1002/cam4.1098
https://doi.org/10.1002/cam4.1098
Autor:
Oliver Sartor, Peter Georgantopoulos, Charles L. Bennett, William J. M. Hrushesky, LeAnn B. Norris, Dennis W. Raisch, Brian Chen, Akida Lebby, Robert C. Kane, Sumimasa Nagai, Terhi Hermanson, Y. Tony Yang, Laura R. Bobolts, Samuel Kessler, Joshua J. Riente, Zaina P. Qureshi, James O. Armitage
Publikováno v:
The Lancet Oncology. 17:e493-e501
Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the safety of this class of drugs. In this Series paper, we review clinical, policy, safety, and regulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67bf860d2ec67972dc96835c876c2829
https://doi.org/10.1016/s1470-2045(16)30384-9
https://doi.org/10.1016/s1470-2045(16)30384-9
Autor:
Joseph R. Berger, Charles L. Bennett, LeAnn B. Norris, James O. Armitage, Dennis W. Raisch, Peter Georgantopoulos, William J. M. Hrushesky, Oliver Sartor, Kenneth R. Carson
Publikováno v:
British Journal of Haematology. 180:301-304
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::360d73dd8c48489c437fe0b99ddabd78
https://doi.org/10.1111/bjh.14322
https://doi.org/10.1111/bjh.14322
Autor:
Suvarthi Das, Redd Aj, Oliver Sartor, Saurabh Chatterjee, Jennifer Greene, Richard J. Ablin, Frizzell N, John Bian, Hrusheshky W, Ponemone, Noxon, Brookstaver B, Zaina P. Qureshi, Elraheb Y, Shweta Hegde, Norris Lb, Paul Ray, Anindya Chanda, John Restaino, K. Lu, Gowtham A. Rao, Charles L. Bennett, Dennis W. Raisch, Rorro M, Kamaljeet Kaur, Peter Georgantopoulos, Arpit Saxena, Bryan L. Love, Raja Fayad, Richard M. Schulz, Manjeshwar Shrinath Baliga
Publikováno v:
The Journal of Community and Supportive Oncology. :54-65
Background The 3 fluoroquinolone (FQ) antibiotics - ciprofoxacin, levofoxacin, and moxifoxacin - are commonly administered to oncology patients. Although these oral antibiotics are approved by the US Food and Drug Administration (FDA) for treatment o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9155aad69164dff4eda0fc8c85fa0bdc
https://doi.org/10.12788/jcso.0167
https://doi.org/10.12788/jcso.0167
Autor:
Kathlyn Sue Haddock, Anwar T. Merchant, Salim S. Virani, D.A. Morales, Chanelle J. Howe, Peter Georgantopoulos
Publikováno v:
Journal of Dental Research. 95:408-415
This was a prospective cohort study evaluating 126,805 individuals with diabetes and periodontal disease receiving care at all Veterans Administration medical centers and clinics in the United States from 2005 through 2012. The exposures were periodo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d7eda0f536c3990ce1a45b1ce2390bc
https://doi.org/10.1177/0022034515622197
https://doi.org/10.1177/0022034515622197
Autor:
Bo Cai, Peter Georgantopoulos, Gowtham A. Rao, Christopher T. Emrich, Jan M. Eberth, Kathlyn Sue Haddock, Charles L. Bennett, James R. Hébert
Publikováno v:
Cancer causescontrol : CCC. 31(3)
Racial and socio-economic status (SES) disparities exist in prostate cancer (PrCA) incidence and mortality. Less is known regarding how geographical factors, including neighborhood social vulnerability and distance traveled to receive care, affect Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106a6c79d1c3c18f700e917df816a535
https://pubmed.ncbi.nlm.nih.gov/31975155
https://pubmed.ncbi.nlm.nih.gov/31975155
Autor:
Michael D. Wyatt, James O. Armitage, Melissa Armitage, Z. Kevin Lu, Richard M. Schulz, Paul Ray, Terhi Hermanson, Oliver Sartor, Brian Chen, William J. M. Hrushesky, John Bian, Laura Rose Bobolts, Richard J. Ablin, Zaina P. Qureshi, Charles L. Bennett, Samuel Kessler, Peter Georgantopoulos, Iain C. Macdougall, Dennis W. Raisch, Bryan L. Love, Virginia Noxon
Publikováno v:
The Lancet Oncology. 15:e594-e605
Summary Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents—molecules that are similar in structure, function, act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f53f7f043f6933b800efdc6d199c91a8
https://doi.org/10.1016/s1470-2045(14)70365-1
https://doi.org/10.1016/s1470-2045(14)70365-1
Publikováno v:
Blood. 134:2135-2135
Background : Patients with Chronic Lymphocytic Leukemia (CLL) are susceptible to infections due to impaired immunity, from both complications of disease and treatments. Specific treatments such as fludarabine or rituximab are incorporated in chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7265d395e7931bdfaff7d231d9454346
https://doi.org/10.1182/blood-2019-121770
https://doi.org/10.1182/blood-2019-121770